缬更昔洛韦预防停药后细胞因子和趋化因子分泌组与巨细胞病毒感染风险 - Suppr

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis.

作者信息

Fernández-Ruiz Mario, Parra Patricia, Ruiz-Merlo Tamara, Redondo Natalia, Rodríguez-Goncer Isabel, Andrés Amado, Aguado José María

机构信息

Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.

Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

出版信息

Transpl Int. 2023 Jan 26;36:10979. doi: 10.3389/ti.2023.10979. eCollection 2023.

DOI:10.3389/ti.2023.10979

PMID:36776902

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9908579/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f345/9908579/13ca1bf69600/ti-36-10979-g001.jpg

相似文献

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis.缬更昔洛韦预防停药后细胞因子和趋化因子分泌组与巨细胞病毒感染风险

Transpl Int. 2023 Jan 26;36:10979. doi: 10.3389/ti.2023.10979. eCollection 2023.

Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.在抗体预处理下，使用口服更昔洛韦或缬更昔洛韦对肾移植和胰肾联合移植进行巨细胞病毒预防。

Transplant Proc. 2004 Dec;36(10):3107-12. doi: 10.1016/j.transproceed.2004.11.092.

Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?盐酸缬更昔洛韦（万赛维）对肝移植受者的巨细胞病毒感染有有效的预防作用吗？

Transplant Proc. 2005 Sep;37(7):3182-6. doi: 10.1016/j.transproceed.2005.07.032.

Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.回顾性分析肝移植术后小儿患者巨细胞病毒感染和疾病的发生率：预防性口服更昔洛韦与口服缬更昔洛韦的比较。

Liver Transpl. 2012 Mar;18(3):347-54. doi: 10.1002/lt.22471.

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.口服缬更昔洛韦预防心脏移植患者巨细胞病毒感染的效果

Drug Des Devel Ther. 2012;6:289-95. doi: 10.2147/DDDT.S36578. Epub 2012 Oct 12.

A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients.一项关于缬更昔洛韦预防肺移植受者巨细胞病毒感染的试验。

Am J Transplant. 2005 Jun;5(6):1462-8. doi: 10.1111/j.1600-6143.2005.00866.x.

Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.口服更昔洛韦与低剂量缬更昔洛韦预防肾移植和胰腺移植受者巨细胞病毒病的比较

Transplantation. 2007 Feb 15;83(3):290-6. doi: 10.1097/01.tp.0000251371.34968.ca.

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.更昔洛韦预防治疗可降低肺移植受者 CMV 感染和急性排斥反应的发生率。

BMC Infect Dis. 2013 Dec 10;13:582. doi: 10.1186/1471-2334-13-582.

Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.接受缬更昔洛韦预防治疗的高危肝移植受者与接受更昔洛韦预防治疗的高危肝移植受者相比，巨细胞病毒感染发生率增加。

Liver Transpl. 2009 Aug;15(8):963-7. doi: 10.1002/lt.21769.

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.更昔洛韦预防时代供者阳性/受者阴性肺移植受者中的巨细胞病毒病。

J Heart Lung Transplant. 2010 Sep;29(9):1014-20. doi: 10.1016/j.healun.2010.04.022. Epub 2010 Jul 3.

引用本文的文献

Advancements in Cytomegalovirus Management Among Solid Organ Transplant Recipients: Insights From the ESOT CMV Workshop 2023.实体器官移植受者巨细胞病毒管理的进展：来自2023年欧洲器官移植学会巨细胞病毒研讨会的见解

Transpl Int. 2025 Aug 22;38:14195. doi: 10.3389/ti.2025.14195. eCollection 2025.

Comprehensive Analysis of Soluble Mediator Profiles in Congenital CMV Infection Using an MCMV Model.利用 MCMV 模型对先天性 CMV 感染中的可溶性介质谱进行综合分析。

Viruses. 2024 Jan 30;16(2):208. doi: 10.3390/v16020208.

本文引用的文献

Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.采用 5 种非 HLA 免疫遗传多态性预测异基因干细胞移植后 CMV 再激活的风险。

Ann Hematol. 2022 Jul;101(7):1567-1576. doi: 10.1007/s00277-022-04841-8. Epub 2022 May 7.

High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients.高循环 SDF-1 和 MCP-1 水平以及 CXCL12、CCL2 和 CCR5 的遗传变异：治疗后 HIV 阳性患者免疫恢复状态的预后标志物。

EBioMedicine. 2020 Dec;62:103077. doi: 10.1016/j.ebiom.2020.103077. Epub 2020 Nov 6.

Identification of a novel signaling complex containing host chemokine receptor CXCR4, Interleukin-10 receptor, and human cytomegalovirus US27.鉴定一种包含宿主趋化因子受体 CXCR4、白细胞介素 10 受体和人巨细胞病毒 US27 的新型信号复合物。

Virology. 2020 Sep;548:49-58. doi: 10.1016/j.virol.2020.06.006. Epub 2020 Jun 17.

Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.采用商品化酶联免疫吸附法（ELISA）检测干扰素-γ释放试验监测抗胸腺细胞球蛋白治疗的肾移植受者巨细胞病毒特异性细胞免疫。

Am J Transplant. 2020 Aug;20(8):2070-2080. doi: 10.1111/ajt.15793. Epub 2020 Feb 21.

Accuracy of interferon-γ-induced protein 10 for diagnosing latent tuberculosis infection: a systematic review and meta-analysis.干扰素-γ 诱导蛋白 10 诊断潜伏性结核感染的准确性：系统评价和荟萃分析。

Clin Microbiol Infect. 2019 Jun;25(6):667-672. doi: 10.1016/j.cmi.2018.12.006. Epub 2018 Dec 14.

Pathological roles of the homeostatic chemokine CXCL12.稳态趋化因子 CXCL12 的病理作用。

Cytokine Growth Factor Rev. 2018 Dec;44:51-68. doi: 10.1016/j.cytogfr.2018.10.004. Epub 2018 Oct 23.

CCL8 and the Immune Control of Cytomegalovirus in Organ Transplant Recipients.CCL8 与器官移植受者巨细胞病毒的免疫控制。

Am J Transplant. 2015 Jul;15(7):1882-92. doi: 10.1111/ajt.13207. Epub 2015 Mar 12.

CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications.细胞趋化因子 10/干扰素诱导蛋白 10 在感染性疾病发病机制中的作用及其潜在的治疗意义。

Cytokine Growth Factor Rev. 2011 Jun;22(3):121-30. doi: 10.1016/j.cytogfr.2011.06.001. Epub 2011 Jul 29.

Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis.评估IP-10和MCP-2作为结核病诊断生物标志物的潜力。

Eur Respir J. 2008 Dec;32(6):1607-15. doi: 10.1183/09031936.00055508. Epub 2008 Aug 6.

Overview of interleukin-18: more than an interferon-gamma inducing factor.白细胞介素-18概述：不仅仅是一种γ干扰素诱导因子。

J Leukoc Biol. 1998 Jun;63(6):658-64.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献